Publication for MS4A1 and TCL1A

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	MS4A1	membrane spanning 4-domains A1	931			[link]
hsa	TCL1A	TCL1 family AKT coactivator A	8115

Pubmed ID	Priority	Text
28119695	0.98	TCL1A, SH2D1B, MS4A1, FCRL1, and FCRL2) that were associated with B cell-related pathways.
	0.97	MS4A1, and TCL1A has been shown to be significantly downregulated in renal transplant recipients with acute rejection.
32114394	0.98	MS4A1, CD79A, CRIP1 and IGJ levels and low TCL1A, PMAIP1 levels, indicative of mature B cells (Fig. 3d and e, Table S6 and Fig. S5B in the Supplementary Appendix).
	0.96	B1 and B5 expressed high TCL1A, CD79A, CD79B, MS4A1 levels and lacked CD27 and CD138 expression.
31134051	0.98	Membrane Spanning 4-Domains A1 (MS4A1), CD79B, and T-Cell Leukemia/Lymphoma 1A (TCL1A) were enriched in samples from ITx patients.
31209404	0.98	CD20 (MS4A1), demonstrated upregulation of genes typical of naive B cells, including high levels of IGHD, IGHM, TCL1A and IL4R, and had nearly undetectable expression of CD27; the other cluster (CB2b) expressed genes known to be upregulated in plasmacytoid DCs (pDCs) (Fig. 5c and Supplementary Fig. 5c), including PTPRS, GZMB, CLEC4C, CD123 (IL3RA) and CD317 (BST2).
24184334	0.97	CD20 (MS4A1), T-cell leukemia/lymphoma 1A (TCL1A, transcriptional regulator and AKT mediator abundantly expressed in naive B cells,, Fc receptor-like 1/Fc receptor like 2 (FCRL1/FCRL2, immunoregulatory transmembrane proteins,) and prepronociceptin (PNOC, opioid-like receptor).
	0.96	MS4A1 and TCL1A (Figure 1).
27328267	0.97	TCL1A, SH2DB1, FCRL1, and MS4A1), further strengthening the argument that the expression of genes included in the IoT signature was influenced by IS drug regimens.
	0.97	TCL1A, MS4A1, FCRL2, and CD79B) were included in this 20-gene set, but we now demonstrate that their expression is highly affected by azathioprine and prednisone.
28302172	0.97	TCL1A, RP11-356K23.1, PLD4, DKK3, UBE2QL1, KLRB1, and MS4A1 (Table 3).
30348985	0.97	MS4A1 (protein alias CD20), CD22, CD52 without expression of either CD27 or CD138 which suggest that this cluster is comprised of mature antigen inexperienced B cells (top DE genes: MS4A1, LTB, CD37, CD79B, CD52, HLA-DQB1, TNFRSF13C, TCL1A, LINC00926, STAG3, IGHD, BANK1, IRF8, BIRC3, P2RX5, RP11-693J15.5, RP5-887A10.1, VPREB3, CD22, CD74, SELL).
22617684	0.96	Tcl1 and MS4A1 did not differ among the three groups, which suggests that they are not involved in immune impairment in ESRD patients.
	0.94	TCL1A and MS4A1 mRNA expression levels did not differ between HD and pre-dialysis patients (P > 0.05).
	0.91	TCL1A (A), MS4A1 (B), and BLNK (C) mRNA were measured using real-time PCR.
28860953	0.96	TCL1A, BLNK, MS4A1, EBF1, IGHM are up-regulated in TOL condition.
	0.95	TCL1A, BLNK, MS4A1, EBF1, and FCRL2 were marked as top 5 genes.
27708232	0.95	MS4A1 (CD20), CD24, TCL1A and BLNK (Table 2).
22468229	0.94	CD20, PAX5, SPIB, STAT6, TNF, LRMP, TCL1A, PTPRC (CD45), WEE1, and BCL3 (Fig. 3d).
26299617	0.87	TCL1A+ and CD20+ B cell populations play an essential role in this outcome.
	0.68	TCL1A (green), CD20 (red) and CD19 (blue) shows that TCL1A+ cells predominantly expressed CD19, and some of these cells also expressed CD20.
	0.67	TCL1A (green), CD20 (red) and CD10 (blue) shows that the majority of TCL1A+ cells expressed CD10, and some TCL1A+ cells expressed CD20.
	0.66	CD20 or TCL1A was not significantly correlated with survival (data not shown), although a high ratio of TCL1A/CD20 expression showed a trend towards improved disease-specific survival (p = 0.053).
	0.60	TCL1A+CD19+CD20+ cells or TCL1A+CD19-CD20- cells and patient survival (data not shown), suggesting that TCL1A+CD19+ cells play the most clinically relevant role.
	0.55	TCL1A/CD20 (B cell) ratio, determined in total tumor samples from a separate patient cohort using qRT-PCR (n = 52), was also correlated with improved survival (p = 0.027).
29437791	0.86	MS4A1 (CD20), FCRL2, TCL1A, and BANK1 were among the top 20 most differentially expressed genes (false discovery adjusted p-values <0.01) (supplemental figure 6).
28085915	0.72	TCL1A, CD79A, CD200, MS4A1, FCRL2, HS3ST1 and CCR7) or down-regulated (FN-1, IL-8, C4A) in the TAC-group.